Randomized Multicenter Trial of More Intense and Standard Early Verteporfin Treatment of Neovascular Age-Related Macular Degeneration

Ophthalmology

Volumn 115, Issue 1, 2008, Pages 134-140

  Schmidt Erfurth, Ursula ^a   Sacu, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VERTEPORFIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; RETREATMENT; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 37349055345     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.02.033     Document Type: Article

References (18)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
2. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123 (2005) 448-457
3. Schmidt-Erfurth U., Miller J.W., Sickenberg M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117 (1999) 1177-1187
4. Schmidt-Erfurth U., Michels S., Barbazetto I., and Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 43 (2002) 830-841
5. Michels S., Wachtlin J., Gamulescu M.A., et al. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. Ophthalmology 112 (2005) 2070-2075
6. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
7. Zhang J., Quan H., Ng J., and Stepanavage M.E. Some statistical methods for multiple endpoints of clinical trials. Control Clin Trials 18 (1997) 204-221
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Group, Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no 1. Am J Ophthalmol 136 (2003) 407-418
9. Arias L., Pujol O., Berniell J., et al. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration. Br J Ophthalmol 89 (2005) 312-315
10. Schmidt-Erfurth U., Schlotzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44 (2003) 4473-4480
11. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44 (2003) 2147-2154
12. Schlotzer-Schrehardt U., Viestenz A., Naumann G.O., et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240 (2002) 748-757
13. Schmidt-Erfurth U., Michels S., and Augustin A. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol 124 (2006) 561-563
14. Augustin A.J., and Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 141 (2006) 638-645
15. Augustin A.J., and Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 14-22
16. Eter N., Krohne T.U., and Holz F.G. New pharmacologic approaches to therapy for age-related macular degeneration. Bio Drugs 20 (2006) 167-179
17. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
18. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487